Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DLK1-Fc
- Development stage
- Preclinical
- Lead developer
- Y Biologics
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intperitoneal
01
Overview
DLK1-Fc is a recombinant fusion protein consisting of the extracellular domain of delta-like 1 homolog (DLK1, also known as preadipocyte factor 1 or Pref-1) fused to the Fc region of human IgG1. Originally developed by the Korea Research Institute of Bioscience and Biotechnology (KRIBB) and Y-Biologics, DLK1-Fc acts as a soluble form of DLK1. It has been investigated in preclinical studies for multiple therapeutic indications, including cancer metastasis (specifically liver and pancreatic cancers), obesity, type 2 diabetes, and sarcopenia/muscle atrophy. Mechanistically, DLK1-Fc binds to activin receptor type 2B (ACVR2B) to inhibit myostatin-mediated signaling, thereby preventing muscle wasting. Additionally, it interacts with fibronectin and integrin alpha-5/beta-1 to activate the MEK/ERK pathway, upregulating Sox9 and inhibiting adipogenesis, which reduces fat mass and improves insulin sensitivity.
- Other names
- DLK1-FcDLK-1-FcDLK 1-FcDLK1-hFcDLK-1-hFcDLK 1-hFcDLK1:FcPref-1-FcPref1-FcPref 1-Fcdelta-like 1 homolog-Fcdelta-like1 homolog-Fcdelta-like-1 homolog-Fcpreadipocyte factor 1-Fc
02
Targets
ACVR2B (Activin receptor type IIB)ITGA5 (Integrin alpha-5)ITGB1 (Integrin beta-1)
Beyond the preview
Go deeper on DLK1-Fc.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DLK1-Fc.